Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor

In recent years, the restoration of p53 physiological functions has become an attractive therapeutic approach to develop novel and efficacious cancer therapies. Among other mechanisms, the oncosuppressor protein p53 is functionally regulated by MDM2 through its E3 ligase function. MDM2 promotes p53 ubiquitination and degradation following homodimerization or heterodimerization with MDM4. Recently, we discovered Pep3 (1, Pellegrino et al., 2015), a novel peptidic inhibitor of MDM2 dimerization able to restore p53 oncosuppressive functions both in vitro and in vivo. In this work, we were able to identify the key interactions between peptide 1 and MDM2 RING domain and to design peptide 2, a truncated version of 1 that is still able to bind MDM2. Integrating both computational and biophysical techniques, we show that peptide 2 maintains the conserved peptide 1-MDM2 interactions and is still able to bind to full-length MDM2.

Authors

Institutions

Publication Details

Journal
Bioorganic & Medicinal Chemistry
Published
2024-10-02
DOI
https://doi.org/10.1016/j.bmc.2024.117937
Citations
2
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor

Andrea Temperini, Antonio Macchiarulo, Elisa Bianconi, Marco Ballarotto et al.
2 citations
Bioorganic & Medicinal Chemistry
Monoclonal and Polyclonal Antibodies Research
0.81
article

Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor

Andrea Temperini, Antonio Macchiarulo, Elisa Bianconi, Marco Ballarotto, Fabiola Moretti, Sonia Valentini
article en
2 citations

Abstract

In recent years, the restoration of p53 physiological functions has become an attractive therapeutic approach to develop novel and efficacious cancer therapies. Among other mechanisms, the oncosuppressor protein p53 is functionally regulated by MDM2 through its E3 ligase function. MDM2 promotes p53 ubiquitination and degradation following homodimerization or heterodimerization with MDM4. Recently, we discovered Pep3 (1, Pellegrino et al., 2015), a novel peptidic inhibitor of MDM2 dimerization able to restore p53 oncosuppressive functions both in vitro and in vivo. In this work, we were able to identify the key interactions between peptide 1 and MDM2 RING domain and to design peptide 2, a truncated version of 1 that is still able to bind MDM2. Integrating both computational and biophysical techniques, we show that peptide 2 maintains the conserved peptide 1-MDM2 interactions and is still able to bind to full-length MDM2.

Bioorganic & Medicinal ChemistryVol. 113
University of Perugia (IT), Institute of Cell Biology and Neurobiology (IT)
Associazione Italiana per la Ricerca sul Cancro, Università degli Studi di Perugia
Zero hunger
Openalex Percentile: Top 25%
Monoclonal and Polyclonal Antibodies Research
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor — Andrea Temperini, Antonio Macchiarulo, et al. · Bioorganic & Medicinal Chemistry (2024) | TGRS Research Map | TGRS